[Cardiovascular effects of human atrial natriuretic peptide during pediatric renal transplantation].
We evaluated the cardiovascular effects of human atrial natriuretic peptide (hANP) in the pediatric recipients undergoing renal transplantation. Anesthesia was maintained by inhalation of nitrous-oxide and isoflurane in oxygen. Intravenous infusion of hANP at a rate of 0.05 microg x kg(-1) x min(-1) was started on the anastomosis of the renal artery after the fresh frozen plasma had been loaded to achieve PCWP above 17 mmHg. We examined cardiovascular changes by using a pulmonary artery catheter and transesophageal echocardiography. The measurements were done before and after 15 minutes of hANP infusion. An increase in CI and a reduction in PCWP were significant. The low-dose infusion of hANP was useful in pediatric recipients undergoing renal transplantation for the optimal anesthetic care in view of the improvement of cardiovascular functions.